MNTC Stock Overview
Mentice AB (publ) provides endovascular simulation solutions to teaching entities, healthcare systems, and medical device manufacturers.
Price History & Performance
|Historical stock prices|
|Current Share Price||kr60.00|
|52 Week High||kr185.00|
|52 Week Low||kr50.60|
|1 Month Change||-14.04%|
|3 Month Change||-21.67%|
|1 Year Change||-57.29%|
|3 Year Change||-16.03%|
|5 Year Change||n/a|
|Change since IPO||-11.24%|
Recent News & Updates
Mentice AB (publ) (STO:MNTC) Shares Could Be 44% Below Their Intrinsic Value Estimate
In this article we are going to estimate the intrinsic value of Mentice AB (publ) ( STO:MNTC ) by projecting its future...
|MNTC||SE Healthcare Services||SE Market|
Return vs Industry: MNTC underperformed the Swedish Healthcare Services industry which returned 3.9% over the past year.
Return vs Market: MNTC underperformed the Swedish Market which returned -20.9% over the past year.
|MNTC Average Weekly Movement||6.7%|
|Healthcare Services Industry Average Movement||7.7%|
|Market Average Movement||7.2%|
|10% most volatile stocks in SE Market||12.6%|
|10% least volatile stocks in SE Market||4.5%|
Stable Share Price: MNTC is not significantly more volatile than the rest of Swedish stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: MNTC's weekly volatility (7%) has been stable over the past year.
About the Company
Mentice AB (publ) provides endovascular simulation solutions to teaching entities, healthcare systems, and medical device manufacturers. The company operates through Medical Device Industry, Healthcare Systems, and Strategic Alliances segments. It provides software modules in the areas of acute ischemic stroke intervention, atrial septal defect and patent foramen ovale occlusion, aortic valve implantation, endovascular aortic repair, below-the-knee intervention, carotid intervention, patient-specific simulation, coronary advanced and essentials, coronary intermediate, left atrial appendage occlusion, neurovascular coiling and thrombectomy, peripheral angiography, prostatic artery embolization, radiation safety, renal denervation, renal intervention, thoracic endovascular aortic repair, transarterial chemoembolization, transseptal puncture, uterine artery embolization, peripheral angiography, and vascular trauma and cardiac rhythm management, as well as supports interventionalists to transition from transfemoral to transradial access.
Mentice Fundamentals Summary
|MNTC fundamental statistics|
Is MNTC overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|MNTC income statement (TTM)|
|Cost of Revenue||kr37.16m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
Oct 26, 2022
|Earnings per share (EPS)||-1.43|
|Net Profit Margin||-17.84%|
How did MNTC perform over the long term?See historical performance and comparison
Is MNTC undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 4/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for MNTC?
Other financial metrics that can be useful for relative valuation.
|What is MNTC's n/a Ratio?|
Price to Sales Ratio vs Peers
How does MNTC's PS Ratio compare to its peers?
|MNTC PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
RAY B RaySearch Laboratories
ORTI B Ortivus
Price-To-Sales vs Peers: MNTC is good value based on its Price-To-Sales Ratio (7.5x) compared to the peer average (10.3x).
Price to Earnings Ratio vs Industry
How does MNTC's PE Ratio compare vs other companies in the European Healthcare Services Industry?
Price-To-Sales vs Industry: MNTC is expensive based on its Price-To-Sales Ratio (7.5x) compared to the Swedish Healthcare Services industry average (5.5x)
Price to Sales Ratio vs Fair Ratio
What is MNTC's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||7.5x|
|Fair PS Ratio||9.3x|
Price-To-Sales vs Fair Ratio: MNTC is good value based on its Price-To-Sales Ratio (7.5x) compared to the estimated Fair Price-To-Sales Ratio (9.3x).
Share Price vs Fair Value
What is the Fair Price of MNTC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: MNTC (SEK60) is trading below our estimate of fair value (SEK120.93)
Significantly Below Fair Value: MNTC is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.
Discover undervalued companies
How is Mentice forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score5/6
Future Growth Score 5/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MNTC is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.4%).
Earnings vs Market: MNTC is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: MNTC is expected to become profitable in the next 3 years.
Revenue vs Market: MNTC's revenue (21.6% per year) is forecast to grow faster than the Swedish market (10.9% per year).
High Growth Revenue: MNTC's revenue (21.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MNTC's Return on Equity is forecast to be low in 3 years time (19%).
Discover growth companies
How has Mentice performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MNTC is currently unprofitable.
Growing Profit Margin: MNTC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MNTC is unprofitable, and losses have increased over the past 5 years at a rate of 64% per year.
Accelerating Growth: Unable to compare MNTC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MNTC is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (-3.9%).
Return on Equity
High ROE: MNTC has a negative Return on Equity (-21.42%), as it is currently unprofitable.
Discover strong past performing companies
How is Mentice's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: MNTC's short term assets (SEK149.7M) exceed its short term liabilities (SEK138.5M).
Long Term Liabilities: MNTC's short term assets (SEK149.7M) exceed its long term liabilities (SEK10.2M).
Debt to Equity History and Analysis
Debt Level: MNTC is debt free.
Reducing Debt: MNTC has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MNTC has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if MNTC has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
What is Mentice current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MNTC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MNTC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MNTC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MNTC's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: MNTC is not paying a notable dividend for the Swedish market.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as MNTC has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Göran Malmberg (63 yo)
Mr. Goran Malmberg serves as Group Chief Executive Officer and President at Mentice AB. Mr. Malmberg had been the Chief Executive Officer and President of Mentice AB since March 2008. Mr. Malmberg has exte...
Experienced Management: MNTC's management team is considered experienced (3.6 years average tenure).
Experienced Board: MNTC's board of directors are considered experienced (3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.2%.
Mentice AB (publ)'s employee growth, exchange listings and data sources
- Name: Mentice AB (publ)
- Ticker: MNTC
- Exchange: OM
- Founded: 1998
- Industry: Health Care Technology
- Sector: Healthcare
- Implied Market Cap: kr1.534b
- Shares outstanding: 25.57m
- Website: https://www.mentice.com
Number of Employees
- Mentice AB (publ)
- Odinsgatan 10
- Västra Götaland County
- 411 03
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/16 00:00|
|End of Day Share Price||2022/08/16 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.